

Fax completed prior authorization request form to 844-802-1412 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

Aetna Better Health®

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned

Pharmacy Coverage Guidelines are available at https://www.aetnabetterhealth.com/Illinois-medicaid

Cytokines and Cell Adhesion Molecule (CAM) Antagonists Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

						ale	□ Fe	male				
Member ID: City:					State:	·			Weight:			
Prescribing Provider Information												
Provider Name (first &	Specialty	Specialty:					DEA#					
Office Address:		City:	City:				Zip Code:					
Office Contact:				e Phone	1	Office Fax:						
Dispensing Pharmacy	Information						1					
Pharmacy Name:			Phar	Pharmacy Phone: Pharmacy Fax:								
Requested Medication	n Information											
Preferred Agents:	☐ Humira	□ Enbrel		□ Cin	Cimzia 🗆		eljanz E		l Xeljanz XR			
No. B. G. and				П. О.					01 ::			
Agents:	Ion-Preferred				sentyx	□ Talt			Skyrizi			
	□ Ilaris	□ Ilumya		☐ Kin	eret	☐ Siliq			1 Simponi Aria			
☐ Orencia		□ Renflexi	s	□ Tremfya		☐ Tysa	abri] Inflectra			
	☐ Olumiant [de	☐ Simponi ☐ S			ara					
	☐ Other, please s	pecify:										
Medication request is compendia-supported	r Diag	Diagnosis: □ ICD-10 Code:										
Are there any contraine	f yes, sp	/es, specify):				□ New □ Continuerequest of thera						
Directions for Use:	Strer	Strength: Dosage Form:										
	Quar	ntity:	Day Supp	oly:	Duration of Therapy/Use:							
What medication(s) has the member tried and failed for this diagnosis? Please specify below.												
Turn-Around Time for	Poviow											
☐ Standard – (24 hours) ☐ Urgent – waiting 24 hours for a standard decision could seriously harm life, health,										nealth.		
	,	bility to regain maximum function, you can ask for an expedited decision.										
		ture:										
Clinical Information		, 										
General Authorization	Criteria - ALL Agents	s and Indicatio	ns:									
Is member on another Cytokine or Cell Adhesion Molecule (CAM) Antagonist?										No		

Is request for an Anti-Tumor Necrosis

| Sector | Sector

Is request for Anti-Tumor Necrosis Factors such as Stelara, Xeljanz, Xeljanz XR, Kineret, Actemra, Ilaris OR													
Orencia? Was a screen completed for Hepatitis B? □ Yes □ No Does member have active								□ Yes	□ No				
If member has active OR chronic Hepatitis B, is member receiving appropriate antiviral								l 10 □	N/A				
If member has active OR chronic Hepatitis B, is member receiving appropriate antiviral The second of the second o													
Was member evaluated AND give	en approp	riate vaco	ination	s, as reco	mmended per CDC	for risk fact	ors?	□ Yes	□ No				
Was member screened for	□ Yes	□ No	If sc	reening w	as positive for latent	t 🗆 '	Yes 🗆 N	10 D	N/A				
TB?		TB, was treatment received for latent											
		TB?											
Is request for Entyvio or	□ Yes	□ No	Is us	□ Yes	□ No	□ N/A							
Tysabri?	with antineoplastic, immunosuppressive OR												
					llating agents (AZA,								
Additional Oritoria Based on In-	diaatian.		cycl	osporine,	MTX, TNF inhibitors)							
Additional Criteria Based on Inc	alcation:												
Was there inadequate response	to 2	☐ Ye	s 🗆	No Wa	as there intolerance	OP control	adication to		es 🗆 No				
month trial of MTX?	10 3-	L Te	, 🗀		TX?	OR COITH an	idication to		es L NO				
Were SSZ, LEF or HCQ used due	, to	☐ Ye	s 🗆		III requested medica	tion he use	4	□ Ye	es 🗆 No				
intolerance OR contraindication			, _		ncurrently with MTX				B3 L 110				
micoranos en contramacatori	to with.				MARD such as SSZ, L		_						
☐ Systemic Juvenile Idiopat	hic Arthriti	S											
Does member have ACTIVE SYS			uch as f	ever, evar	nescent Is synovi	tis in ONE C	R MORE JO	INTS despi	te 3 months				
rash, lymphadenopathy, hepato	megaly, sp	lenomega	ıly OR s	erositis? (circle treatmen	nt with MTX	OR LEF? (cir	rcle one):					
one):						Yes	No)					
Yes	N	0											
Check if one of the following There are ACTIVE SYSTEMIC FEATURES such as fever, evanescent rask									enopathy,				
apply:					ly OR serositis AND	-							
					EMIC FEATURES suc				NIE OD				
	-	-		-	negaly, splenomegal nths treatment with	-	-	ovitis is in <u>C</u>	<u>INE OR</u>				
There are ACTIVE SYSTEMIC FE				•	ynovitis is in <u>ONE OF</u>			a 1-month	treatment				
evanescent rash, lymphadenopa			JI,		ith <u>Kineret OR Acter</u>		-		trodunone				
splenomegaly, or serositis (circle		Yes		No	Yes		. <u>.,, o.</u> (o. No	. 0.0 00,.					
□ Polyarticular Juvenile Idio		hritis											
Was there inadequate response	_		h MTX?	?	□ Yes	□ No							
Was there an intolerance OR	□ Yes	□ No		N/A V	/as there trial with S	SZ OR LEF	☐ Yes	□ No	□ N/A				
contraindication to MTX?					or 3 months?								
☐ Oligoarticular Juvenile Idi	opathic Ar	thritis											
Is disease duration > 6	□ Yes	□ No		there doo		□ Yes	, indicate dr	ug	□ No				
months?				•	sponse OR								
					e effect with 2								
Did member have contraindicat	on to NSAI	Ds? □	Yes	IDs? □ No	□ N/A								
							I =						
Did member have inadequate re intolerable side effect to 3-mont	-		Yes	□ No	Was there docum of LEF or SSZ for 3		□ Yes	□ No	□ N/A				
MTX?	n mai wim				01 LEF 01 332 101 3	o monuns?							
☐ Cryopyrin-Associated Per	iodic Synd	romes											
Indicate if ONE of the following		amilial Co	ld Auto)	☐ Muckle-Wells	 S	☐ Neonatal onset multi-system						
subtypes is present:		nflammat			syndrome			nmatory dis	-				
Was there 3-months trial with Ki					□ No		1						
☐ Familial Mediterranean Fe	ver												
Was there inadequate response	, intoleranc	e OR con	traindic	ation to co	olchicine at MAX ind	dicated	□ Yes	□ No					
dose?													
☐ Giant Cell Arteritis													

Effective: 10/01/2020 Page 2 of 4

Was there inadequate response with glucocorticoids (for example prednisone, methylprednisolone?						Yes	□ No			intoler ication			oids?		Yes		No
If member had intolerance OR contraindication to glucocorticoids, was there a TRIAL with MTX OR cyclophosphamide?					o 🗆	Yes	□ No		N/A	in con taperi	nedicati nbination	on with			Yes		No
_	Anlandasina Coa									gluco	cortico	ds					
□ Ankylosing Spondylitis Was there inadequate response □ Yes □ No Is there contraindication OR □ Yes □												No		N/	^		
Was there inadequate response to ONE-month trial of TWO NSAIDs? ☐ Yes ☐							erance to o		-			165		INO		INZ	^
	Psoriatic Arthri	tis	1										_		1		
Does member have ☐ Yes ☐ No V ACTIVE Psoriatic Arthritis?								ate response to 3-months trial with MTX?							No		
con	s there intoleranc straindication to M	ITX?	Yes [/A Was there 3-month trial of SSZ OR LEF? □ Yes □									No	
	isease predomina														Yes		No
to C	s there inadequat DNE-month trial o AIDs?	f2	□ Yes	S C] No	OR	Was there contraindication OR intolerance to oral NSAIDs?										
	Plaque Psoriasi				T							T		T		1	
MT	Was there inadequate response to ☐ Yes ☐ MTX OR cyclosporine for ≥3 months?					COI	as there int ntraindicat closporine	tion to	MTX	OR			res		No		N/A
ls>	10% BSA affected	! ?		Yes	□ No	ls •	<10% BSA	affect	ted BU	T involv		sitive a	reas		Yes		No
Is Psoriasis Area and Severity Index									feet, face OR genitals? upy PUVA, UVB ineffective?								No
score >10?												_	N1 -				
For Siliq only: Does member have history of prior suicide attempt, bipolar disorder OR department of the bipolar disorder OR department of the bipolar disorder OR psychiatrist?									essive o	usorae	r?		Yes Yes		No No		
was a mental nealth evaluation completed by prescriber OR psychiatrist? ☐ Yes ☐ No ☐ Ulcerative Colitis																	
☐ STEROID A relapse occurred within 3-months of stopping DEPENDENT glucocorticoids (circle one): Yes No									There is Inability to taper steroids to acceptable dose after 3 months W/O having symptom recurrence:(circle one): Yes No								
☐ STEROID Inadequate response OR intole glucocorticoids after 7-10 days								V	Inadequate response OR intolerable side effect to oral prednisone ≥40mg per day after 30 days (circle one): Yes No								
	Crohn's Disease)															
□ STEROID A relapse occurred within 3-months of stopping DEPENDENT glucocorticoids (circle one): Yes No There was inadequate respons effect, with 3-month trial of 6-N MTX (circle one): Yes																	
				acceptable dose There was contraindication to 6-MP, AZA, AND													
after 3 months W/O having sy						m rec	urrence		injectable MTX (circle one): Yes No								
	REFRACTORY effect to IV glucocorticoids after 7-10 days (circle one): effect							There was inadequate response OR intolerable side effect to oral prednisone ≥40mg per day after 30 days (circle one): Yes No									
	Hidradenitis Su	ppurativa - A								•							
Does member have moderate to severe disease (Hurley stage II-III)?					□ No	oral		such	such as doxycycline, minocycline OR							No	
	Uveitis					Jank		. 50 1 1 11	p	•						<u> </u>	
					e was inadequate				osporin	е 🗆	tacro	limus		Corti	coste	roids	
at all a				esponse				MTX 🗆 AZA				MMF					
caused by infection? SIGE Are medications such as corticosteroids, MTX, AZA, N							following:	ND ±	aual!	NOT					Ver		NI-
			roias, M	11X, A2	LA, MMF,	cyclo	sporine, Al	טעו ta	croum	us NO I	approp	riate?			Yes		No
	Cytokine Releasing iagnosis grade 3		D lifo +L	restor	ning dua t	to ohin	neric antic	ion ro	cantar	-T 00ll 4	horan	2			Yes		No
													au a: -1-				
Add	ditional informati	on tne prescr	ioing pi	ονιαει	r reels is	ımpor	tant to thi	s rev	ew. P	rease s	ресіту	pelow	or sub	mit n	ieaica	rec	oras

Effective: 10/01/2020 Page 3 of 4

Signature affirms that information given on this form is true and accurate and reflects office notes.									
Prescribing Provider's Signature: Date:									
Please note: Incomplete forms or forms without the chart notes will be returned									

Office notes, labs, and medical testing relevant to the request that show medical justification are required. Standard turnaround time is 24 hours. You can call 866-329-4701 to check the status of a request.

Effective: 10/01/2020 Page 4 of 4